DE1525541U - - Google Patents

Info

Publication number
DE1525541U
DE1525541U DENDAT1525541D DE1525541DU DE1525541U DE 1525541 U DE1525541 U DE 1525541U DE NDAT1525541 D DENDAT1525541 D DE NDAT1525541D DE 1525541D U DE1525541D U DE 1525541DU DE 1525541 U DE1525541 U DE 1525541U
Authority
DE
Germany
Prior art keywords
iwt
dwr
becomes
bwi
diw
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DENDAT1525541D
Other languages
German (de)
English (en)
Publication of DE1525541U publication Critical patent/DE1525541U/de
Active legal-status Critical Current

Links

Landscapes

  • Developing Agents For Electrophotography (AREA)
  • Exhaust Gas After Treatment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DENDAT1525541D Active DE1525541U (enrdf_load_stackoverflow)

Publications (1)

Publication Number Publication Date
DE1525541U true DE1525541U (enrdf_load_stackoverflow)

Family

ID=826748

Family Applications (1)

Application Number Title Priority Date Filing Date
DENDAT1525541D Active DE1525541U (enrdf_load_stackoverflow)

Country Status (1)

Country Link
DE (1) DE1525541U (enrdf_load_stackoverflow)

Similar Documents

Publication Publication Date Title
Kaku et al. Efficacy and safety of fasiglifam (TAK‐875), a G protein‐coupled receptor 40 agonist, in J apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial
CN100522080C (zh) 外科夹具推进和对准机构
Migliori et al. Tuberculosis management in Europe
Chesney Adherence to HAART regimens
Campbell et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features
Hoenig et al. The nosological position of transsexualism
NO20041941L (no) Doseringsform, utstyr og fremgangsmater for behandling
DE1525541U (enrdf_load_stackoverflow)
Gotuzzo et al. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults
Maibach Glutaraldehyde: cross-reactions to formaldehyde?
Groop et al. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?
Mackay et al. Failure of lithium treatment in established tardive dyskinesia
Hu et al. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes
Conway et al. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective
CA2246407A1 (en) Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa
Berger Theileria velifera demonstrated in cattle in the Eastern Cape Province of the Republic of South Africa
ELLIS-PEGLER The effects of World Health Organization chemotherapy on imported leprosy in Auckland, New Zealand, 1983-90
Leroy et al. 272-PA12 Survival of HIV-infected patients after tuberculosis, Bordeaux, France, 1988–1994
Nesher et al. Recommendations for drug therapy of rheumatoid arthritis in elderly patients
Wong et al. Proposal to Hamas: 6-Week Pause in Strife and Hostage-Prisoner Swap.
Bruyn Study regimen changes
Shabuj et al. Gentamicin in newborn sepsis: Once daily dose versus twice daily dose
Weaver Prehospital thrombolysis in myocardial infarction
Luger Antibiotic treatment of venereal diseases
POUNDER et al. Optimal Conditions for the Design of a Clinical Trial in Helicobacter pylori